|
|||
|
Frau Caroline Bosch-Voskens
|
Research Interests:
Special clinical interests:
Selected References:
Voskens C. J.; Schroth M.; Bauerschmitz J.; et al. Transition of pityriasis lichenoides et varioliformes acuta into febrile ulceronecrotic Mucha- Habermann disease in a nearly 2 year old boy under oral therapy with steroids. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 2011,9,Suppl.1,160-160
Voskens C. J.; Sticherling M. New-onset psoriasis in a patient treated with Natalizumab. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT 2011,9,Suppl.1,216-216
Voskens CJ, Watanabe R, Rollins S et al. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res 2010 Oct 11;29:134
Zhang X, Voskens CJ, Sallin M et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010 Jan 15;184(2):787-95
Voskens CJ, Strome SE, Sewell DA. Synthetic peptide-based cancer vaccins: lessons learned and hurdles to overcome. Curr Mol Med 2009 Aug;9(6):683-93. Review
Taylor RJ, Chan SL, Wood A, Voskens CJ et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009 Jul;58(7):997-1006
Chan SL, Voskens CJ, Lin W et al. Epitope mapping of a chimeric CD137 mAb: a necessary step for assessing the biologic relevance of non-human primate models J Mol Recognit 2009 May-Jun;22(3):242-9
Lin W*, Voskens CJ*, Zhang X et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood 2008 aug 1;112(3):699-707.
*Authors contributed equally to this publication
